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Magnetic composite biomaterials for tissue
engineering
Sara Gil and João F. Mano*
Magnetic nanoparticles (MNPs) have been increasingly used in tissue engineering and regenerative medi-
cine. These particles have been mainly employed as elements directly incorporated into cells or interact-
ing with cell membranes; however, MNPs are now being combined with biomaterials to create other
functionalities of the structural framework used to support cells, namely for controlling cellular responses
and for enhancing drug delivery and release. This mini-review summarizes and highlights the latest
developments and applications of polymeric/ceramic biomimetic scaﬀolds and hydrogels that contain
MNPs for such purposes, also addressing future perspectives for the use of these magnetic composite
biomaterials in biomedicine.
Introduction
Magnetic materials have been widely used in biomedicine. The
preparation of stronger and smaller permanent magnets
allowed the creation of more delicate biomedical applications
like in the fields of ophthalmology (magnetically assisted
cataract surgery), dentistry (temporary fixing prosthesis),
cardiology and gastroenterology (guiding catheters through
the body), and neurology (navigating within the brain).1 In par-
ticular, much eﬀort has been devoted to the synthesis of mag-
netic nanosized materials, due to their small size and unusual
superparamagnetic properties.2–5 Magnetite (Fe3O4) and
maghemite (γ-Fe2O3) are the most common iron oxides used
in biomedicine due to their low toxicity, relative ease
of functionalization and high magnetization at room
temperature.5–8 Such materials are easily fabricated into the
shape of nanoparticles.9 Magnetic nanoparticles (MNPs)
exhibit a superparamagnetic behavior at sizes below 20 nm,
demonstrating high potential for in vivo applications because
they do not retain any remanent magnetization upon removal
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of the magnetic field, which prevents aggregation and enables
them to redisperse rapidly after withdrawing the magnetic
field.3,5,8,10
MNPs and magnetic liposomes have been increasingly
exploited in the field of biomedicine. They have controllable
size (from a few nanometers up to tens of nanometers) which
is compatible with those of viruses (20–450 nm), proteins
(5–50 nm) and genes (2 nm wide by 10–100 nm long). Besides
their small size, nanoparticles and liposomes can be function-
alized with other materials enabling their interaction and
specific binding to other biological entities, and enhancing
their colloidal stability and biocompatibility. Also, through the
action of a magnetic field it is possible to trace and control the
localization of these nanomaterials within the human body,
through minimally invasive methods.3–5
Tissue engineering (TE) is an interdisciplinary field, exploit-
ing biological and engineering principles that, when combined
with suitable biochemical factors, allows for the development
of functional substitutes for lost or damaged tissue.11 An
emerging TE strategy, named magnetic-force based tissue
engineering, employs cells that have been magnetically labeled
with MNPs or magnetic cationic liposomes (MCLs) in the bio-
fabrication of more complex tissue constructs.8,12 For example,
the cellular culture and co-culture techniques applying this
principle can be used in magnetic cell patterning, magnetic
cell seeding and magnetic cell levitation.12 Such work mainly
focused on the direct contact between MNPs or MCLs and
cells. In another perspective, magnetic elements can be com-
bined with biomaterials that are usually used as structural
frameworks for supporting cells to attach, proliferate and
diﬀerentiate. Such a strategy could allow for the production of
hybrid structures with enhanced functionalities, including
devices that are able to provide mechanical stimuli to cells or
to deliver on demand growth factors (GFs) or other bioactive
molecules. This mini-review provides an overview of the latest
developments of polymeric/ceramic scaﬀolds and hydrogels
that contain magnetic particles for such purposes. The results
reported so far indicate increased interest of researchers in
these topics, foreseeing that magnetic particles can be used as
stimuli to influence cellular activity, as well as cell proliferation
and diﬀerentiation, and will bring new prospects and major
improvements to the fields of drug delivery and tissue
regeneration.
Cellular behavior
Stem cell behavior is highly influenced by the physical pro-
perties of the scaﬀold and the chemical/biochemical land-
scape over its surface. However, other external factors may
aﬀect cellular behavior, such as mechanical stimulation. Many
studies have shown that cell and tissue growth increase in
response to mechanical stresses generated by the mobility of
the surface matrix or by fluid flow.13–15 This has been the basis
for the development of bioreactors.16
Mechanotransduction is a well known pathway by which
cells convert physical stimuli into biochemical activity. For
many TE and regenerative medicine applications, mechanical
cues provide important stimuli to the cells that promote
the production of functional tissue matrix. For example, the
diﬀerentiation of mesenchymal stem cells into bone, cartilage,
muscle and connective tissue is particularly conditioned by
mechanical cues.17,18 However, applying the correct stress pro-
files to cells growing in a 3D scaﬀold within a bioreactor or
within a patient’s body has proven diﬃcult.
To provide mechanical stimuli similar to those experienced
in vivo by cells, the in vivo environment must be mimicked
inside the bioreactor. Currently, the available bioreactors do
not allow the application of spatially varying stresses in three
dimensions in order to form complex tissue structures. Direct
magnetic actuation can provide the application of controlled
forces in order to precisely regulate cellular functions. In this
context, MNPs can be attached to specific ion channels
present on the cellular membrane, acting as stress genera-
tors.19 Cells can thus be mechanically conditioned by mag-
netic remote actuation. Cartmell and co-workers demonstrated
that mechanical stimulation of primary human osteoblast
cells by adhered magnetic particles promoted the regeneration
of the bone matrix when under the influence of a magnetic
field.20
However, a possibility that has seldom been considered is
the application of MNPs in tissue regeneration by incorporat-
ing them into scaﬀolds. These superparamagnetic scaﬀolds
can be “activated” through the application of an external mag-
netic field. The field acts on the nanoparticles along the gradi-
ent vector, producing compressive or tensile forces that are
sensed by the cells in the scaﬀold (Fig. 1). The forces necessary
to activate the mechanosensitive channels via cell membrane
deformation are really small (on the order of picoNewtons).21
Therefore we believe that superparamagnetic scaﬀolds can
provide the necessary cues for stimulating stem cell
diﬀerentiation.
X. B. Zeng and co-workers investigated the behavior of rat
osteoblast and mice preosteoblast cells on a series of MNP-
hydroxyapatite (HA) magnetic scaﬀolds with diﬀerent MNP
contents (from 0 to 2 wt%).22 The results demonstrated the
positive influence of MNP-HA scaﬀolds on cell adhesion, pro-
liferation and diﬀerentiation when compared to non-magnetic
HA scaﬀolds, suggesting enhanced cell behavior due to the
incorporation of MNPs.14,22 Furthermore, these results were
significantly intensified when the MNP-HA scaﬀolds were
under the influence of an external static magnetic field,
suggesting a likely synergistic eﬀect between the magnetic
scaﬀolds and the exterior magnetic field.22–24 Likewise, a posi-
tive correlation between MNP content and cell proliferation
was observed.
With sizes of 20 nm or less, MNPs become superparamag-
netic and behave like common materials in the absence of an
external magnetic field. However, at the nanoscale level, each
MNP in the scaﬀold acts like a single magnetic domain, pro-
viding micromotions at the interface between cells and the
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scaﬀold that might aﬀect the ion channels on the cell
membrane, and trigger the mechanotransduction pathway.25
Nevertheless, as explained earlier, once MNPs are exposed
to a magnetic field, they are rapidly magnetized providing
enhanced therapeutic eﬀects.26
Although the majority of research groups attribute the
direct eﬀect of MNPs on cell activity only to magnetism, we
cannot rule out the possibility raised by Y. Sapir and co-
workers, which states that in addition to the scaﬀold magnetic
properties, the integration of MNPs into the scaﬀolds also
changes the surface roughness of the scaﬀold pore walls and
scaﬀold stiﬀness.27 In fact, scaﬀold elasticity properties are
known to influence cell behavior.28–30 Adhesive forces are
formed when a cell binds to a certain substrate. These forces
are generated by the cellular cytoskeleton, allowing the cell to
spread. Substrate stiﬀness is a parameter that allows control-
ling cell behavior and the extent of cell spreading (Fig. 1).31,32
Sapir et al. observed an enhanced eﬀect on metabolic cell
activity in the MNP-scaﬀold when exposed to a magnetic field.
They did not report an increase in proliferation, but rather an
induction of other cellular processes such as cell organiz-
ation.27 However, to clarify whether this is solely due to the
magnetic component of the scaﬀolds, it would be interesting
to perform a more systematic study, where a scaﬀold impreg-
nated with non-magnetic particles, but with the same elastic/
storage modulus as an MNP impregnated one, would act as a
control.
It can be concluded that magnetic scaﬀolds clearly have an
influence on cellular aspects such as adhesion, proliferation
and diﬀerentiation. The MNP-impregnated scaﬀolds demon-
strate an enhanced eﬀect on cell behavior, promoting the
remote activation of the mechanotransduction pathway which
in turn triggers the biochemical one. Magnetic scaﬀolds
present an excellent alternative and improvement in bioreactor
and scaﬀold design, as they can provide mechanical cues that
can be enhanced upon the application of a remotely generated
external magnetic field. From the research done so far, it is
evident that few papers have clearly studied the mechanism by
which cell behavior is influenced. Some authors attribute such
diﬀerences to scaﬀold magnetic properties, which are synergis-
tically enhanced when under the action of a magnetic field,
but others also state that changes in surface topography
and scaﬀold stiﬀness are parameters that also need to be
considered. In the future it would be important to increase the
systematization of the studies related to the fundamental
understanding of the eﬀect of the presence of MNPs in
Fig. 1 (A) Representative scheme showing some possible beneﬁts and capabilities of using magnetic nanocomposite biomaterials in tissue engin-
eering. I – Magnetic nanoparticles, carrying drugs or growth factors, injected in the vicinity of the scaﬀold and attracted to it upon application of a
magnetic ﬁeld. II – Drug release upon vibration of magnetic nanoparticles. Diﬀerent release proﬁles can be obtained according to the diﬀerent mag-
netic stimuli they are exposed to. III – Magnetic scaﬀold ﬁxation. (B) In the magniﬁed image it can be seen how the magnetic stimulation can
inﬂuence cellular behaviors. On the one hand, at the nanoscale level, each magnetic nanoparticle in the scaﬀold acts like a single magnetic domain,
providing micromotions at the interface between cells and the scaﬀold that might aﬀect the ion channels on the cell membrane, and trigger the
mechanotransduction pathway. On the other hand, the incorporation of magnetic nanoparticles increases scaﬀold stiﬀness, which is a property
known to inﬂuence cell adhesion.
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For the complete biological and histomorphological matu-
ration of tissues, synthetic systems, able to control the delivery
of bioactive systems, are particularly promising as devices for
enhancing tissue regeneration. Therefore scaﬀolds capable of
mimicking the molecular regulatory characteristics, combined
with an adequate three-dimensional (3D) architecture, are
necessary for guiding functional angiogenesis, for controlling
stem cell proliferation and diﬀerentiation, and for tissue
repairing.33,34
Through the introduction of MNPs into the scaﬀold, unique
properties are imparted to the resulting material. In particular,
nanocomposites sensitive to the magnetic field exhibit the
specific property of being responsive to remote actuation, thus
allowing high control of the release of therapeutic agents by the
influence of an external magnetic field.
Controlled drug delivery is mainly aimed at the sustained
delivery of therapeutic substances over a prolonged period of
time. Nevertheless, pulsatile drug delivery is also very attrac-
tive.35 Through an adequate scaﬀold design and time/intensity
control of the external field one could, in principle, achieve
zero-order or more complex (e.g. pulsatile) delivery profiles,
capable of mimicking the physiological needs of bioactive
agents, and thus leading to optimum drug delivery.36
The use of magnetic scaﬀolds responsive to an “on
demand” magnetic field allows overcoming of the limitations
faced by conventional scaﬀolds. These are often pre-loaded
with GFs or other therapeutic molecules, resulting in devices
with limited control of the release profile.37,38 Also, systems
with a constant release rate, very popular in the pharma-
ceutical field, may not be adequate in TE strategies. The body’s
need for a drug during a regenerative process is not always
constant;38 thereby it is believed that magnetic scaﬀolds could
provide a controlled delivery that could be compatible with the
endogenous production and availability of GFs, hormones and
other bioactive molecules.
Such principles were already validated in the field of drug
release systems, especially using composite hydrogels. For
example, R. Langer and co-workers designed a magnetic sub-
cutaneous implant based on ethylene-vinyl acetate copolymer
(EVAc) hydrogels able to liberate insulin at higher rates, upon
demand.39 When the device was implanted in diabetic mice
the glucose level was maintained at a nearly constant value.
However, when a magnetic field was applied the blood glucose
level clearly decreased. The movements induced by the field
on the magnet inside the implanted hydrogel exerted pressure
on the implant’s matrix, causing the squeezing of the drug out
of the pores. Therefore the control of the delivery of insulin
could be achieved by diﬀerent parameters such as the fre-
quency, strength and duration of the external magnetic field.
V. M. Paoli and co-workers studied the eﬀect of an oscillat-
ing magnetic field on the morphology and release profile of
dextran-Rhodamine (Dex-R) from magnetic collagen hydrogels
containing nanoparticles and microparticles. Regarding drug
release profiles, it was observed that the release rate followed
an exponential profile for both formulations. However the
amount of drug released is almost doubled upon application
of the magnetic field.40
The change in the release profile in the system described is
limited to the control of the magnification of the release when
the field is turned on. However, we consider that the combi-
nation of diﬀerent magnetic stimuli with the design and com-
position of hydrogel structures could bring new perspectives to
the drug delivery field and help to obtain release profiles other
than first order release. For example, S. Y. Chen and co-
workers fabricated a magnetic hydrogel by mixing poly(vinyl
alcohol) with Fe3O4 MNPs through freeze–thawing cycles, and
studied the drug release profile when under a pulsed magnetic
field.41 When the field is “switched on” MNPs aggregate
together instantly, producing a bulk magnetic moment and
causing a rapid reduction of the hydrogel’s porosity. In this
state, the rate of drug release is at a lower level and the hydro-
gel possesses a “closed” configuration. However, when the
magnetic field is “switched oﬀ”, the hydrogel returns to its
original geometrical conformation (swelling rate increases)
resulting in a burst-like release profile that turns back to the
normal diﬀusion mode shortly after the burst. On the other
hand, other groups reported diﬀerent results, stating that the
application of an external magnetic field causes a rapid burst
in the drug release.36 Again, considering the design of the
scaﬀolds, they could also be advantageous for the stabilization
of drugs or GFs if those were attached to MNPs that are
impregnated in the scaﬀold. In this way they would always be
available for cells encapsulated within the scaﬀold as opposed
to the dispersed molecules.42,43
The studies performed so far have thus shown that hydro-
gels containing magnetic elements may exhibit distinct, and
even opposite, drug release behaviors upon the action of an
external magnetic field. In the future, we could even envisage
more sophisticated devices. For example, the combination of
magnetic nanoparticles with responsive polymers44 could
open new prospects for externally mediated treatments in vivo
not only including drug release, but also hyperthermia and
combinations thereof.45
In tissue engineering there is a constant need for a spatially
controlled delivery of cells and/or specific GFs to foment rapid
and well organized cell scaﬀold colonization. However, there is
a limitation on the amount of biological material that can be
incorporated into a scaﬀold before implantation. In this
context, magnetic responsive scaﬀolds can be also envisaged
as reloading systems for long term biochemical stimuli. Such
scaﬀolds could function as fixed stations capable of attracting
and fixing, for example nano/micro-magnetic particles con-
taining the required therapeutic molecules via magnetic
Minireview Biomaterials Science


































driving. These particles could be administrated on demand
and be directed to the implanted scaﬀold, delivering the cargo
in that place.
Although magnetic responsive composites have been deve-
loped for the delivery of therapeutics to treat diﬀerent diseases,
they are not yet optimized to be used specifically for regenera-
tive purposes. We believe that there is immense potential for
both fundamental and applied research in this field that
should clearly need the cooperation of multidisciplinary
teams.
Tissue regeneration
Strategies used nowadays for tissue regeneration do not often
promote a successful growth of tissue nor the complete inte-
gration of scaﬀolds into the tissue. Successful regeneration
largely depends on interface interactions between cells
and scaﬀolds. Therefore, scaﬀolds should not act as static
elements. They should be “activated” during cell colonization,
re-structuring their architecture according to the diﬀerent
mechanical and anatomical characteristics and to the diﬀerent
maturation phases of the tissue. As previously discussed, one
of the most important stimuli that promote cellular diﬀeren-
tiation into bone, cartilage, muscle and connective tissue is
the mechanical one, and magnetic stimulation emerges as a
possible means of achieving this stimulation in vivo.
The application of static or alternating magnetic fields in
clinical studies has already been reported by some groups, and
has been proven beneficial in regeneration, integration, and
in-growth of tissues into ceramics.46,47 Also, as commented
before, the incorporation of magnetic nanoparticles into
scaﬀolds used in tissue engineering has already been validated
as having a beneficial role in cellular behavior in in vitro
studies. Therefore, we consider that the incorporation of MNPs
into scaﬀolds acting synergistically with the magnetic field
in vivo would improve cellular proliferation and diﬀerentiation,
and promote an enhancement in tissue integration into the
scaﬀold, a crucial step towards the clinical applications of the
composites. Besides, another factor that should be taken into
consideration is the fixation of scaﬀolds in the defect that
could, in principle, be improved with the help of an external
magnetic field (Fig. 1). An eﬃcient mechanical fixation would
prevent macro and microscopic movements at the interface
between the scaﬀold and body tissue, thus enhancing inte-
gration of the newly formed tissue.
M. Marcacci and co-workers demonstrated for the first time
how collagen magnetic scaﬀolds, fixed in vivo with external
magnets, could induce controlled regeneration in a good 3D
pattern.48 Under the eﬀect of the static magnetic field the
scaﬀolds become “activated” and oriented according to the
field, thus allowing an oriented ECM deposition, which
mimics the site specific collagen/apatite orientation.49
In vivo studies of tissue formation and enhancement
mediated by magnetic or superparamagnetic responsive com-
posites have been rarely reported, although pioneering studies
have demonstrated valuable improvements in tissue regener-
ation.24,50,51 In addition to magnetic biomaterial properties,
the synergistic eﬀect of an external magnetic field results in
the site specific oriented tissue architecture that shortens
tissue remodeling by accelerating the balance between mature
tissue formation and scaﬀold degradation. Moreover, this
methodology allows one to reduce the strength of the magnetic
field applied to the tissues, since weak magnetic force stimu-
lation has a significant eﬀect on the scaﬀold, and consequently
on tissue formation and homogeneity, and on the stability of
the scaﬀold when implanted in the injured site.
Therefore, TE using magnetic composites holds great
promise, since it is beneficial in optimizing the control of
timing, delivery of GFs, magnetic strength and scaﬀold fixation
in tissue formation allowing control of the processes governing
interface regeneration and homeostasis.
Conclusions and future perspectives
Nowadays, magnetic iron oxides, especially in the form of
MNPs, are being used in TE applications. In particular, MNPs
are being incorporated into scaﬀolds, providing functional 3D
engineered systems which can respond to external magnetic
field stimuli.
Such magnetic responsive composites can provide other
functionalities to implantable devices, either by directly influ-
encing the interaction of the scaﬀold with the cells (aﬀecting
adhesion, proliferation and diﬀerentiation) or by their use as
smart drug delivery and tissue regeneration systems. Figure 1,
resumes some eﬀects that can be explored by such devices in
the context of TE, considered in this mini-review. Regarding
cell interactions it was possible to conclude that MNPs stimu-
late cell adhesion, proliferation, and even diﬀerentiation, this
eﬀect being amplified in the presence of an external magnetic
field. Magnetic composites can thus provide local mechanical
stimuli to cells, enhancing the regeneration potential of
implantable devices.
The magnetic properties of polymeric matrices, especially
hydrogels, also allow fine tuning and accurate controlling of
drug’s release profile in the spatiotemporal context. More work
will be necessary in order to improve the drug release profile
(including multiple drug release specifically designed to
stimulate the regenerative process) using magnetic scaﬀolds in
the presence of a magnetic field.
Furthermore, it is believed that magnetic composites could
be useful tools for controlling the delivery and availability of
GFs for tissue regeneration, being more cost eﬀective when
conjugated with magnetic nanoparticles than when freely avail-
able. Moreover, remote actuation could allow for scaﬀold reload-
ing with these molecules, thus benefitting tissue regeneration.
Also, magnetic scaﬀolds can be fixed in the body by the action
of an external magnetic field, overcoming issues related to
scaﬀold micro- and macro-movements in injured sites.
Besides the applications discussed in this review, magnetic
composites could oﬀer other possibilities that could be
explored in the field of TE. For example, Utkan Demirci and
co-workers developed a technique that enables 3D microgel
Biomaterials Science Minireview


































assembly by mimicking the repeating cellular functional units
that compose tissues.52 The technology presented herein
oﬀers an alternative to known approaches, which face cell
seeding limitations and microenvironment control.
Also we envision for the future other kinds of applications,
such as magnetic responsive surfaces that could control better
the cellular behavior, implantable constructs with the shape
controlled by magnetic fields, magnetic beads for stem cell
expansion,53 and magnetic hydrogel composites as remotely
activated microfluidic devices.54
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